Rocket Pharmaceuticals Inc (RCKT)

$25.03

+0.16

(+0.64%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $24.48
    $25.69
    $25.03
    downward going graph

    2.2%

    Downside

    Day's Volatility :4.71%

    Upside

    2.57%

    downward going graph
  • $14.89
    $32.53
    $25.03
    downward going graph

    40.51%

    Downside

    52 Weeks Volatility :54.23%

    Upside

    23.06%

    downward going graph

Returns

PeriodRocket Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
5.25%
5.5%
0.0%
6 Months
-10.7%
7.2%
0.0%
1 Year
39.09%
9.3%
0.0%
3 Years
-36.2%
13.0%
-19.9%

Highlights

Market Capitalization
2.2B
Book Value
$4.87
Earnings Per Share (EPS)
-2.85
Wall Street Target Price
47.17
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.64%
Return On Equity TTM
-55.38%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-257.2M
Diluted Eps TTM
-2.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.76
EPS Estimate Next Year
-2.31
EPS Estimate Current Quarter
-0.68
EPS Estimate Next Quarter
-0.7

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Rocket Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
19
Hold
2
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 88.45%

Current $25.03
Target $47.17

Technicals Summary

Sell

Neutral

Buy

Rocket Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
3.37%
-10.7%
39.09%
-36.2%
95.37%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
NA
NA
NA
-2.76
-0.55
-0.33
NA
4.87
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
Buy
$2.2B
95.37%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Rocket Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 25.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 239.7%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    19.48%
  • Wellington Management Company LLP

    10.09%
  • BlackRock Inc

    6.53%
  • Vanguard Group Inc

    5.92%
  • State Street Corporation

    4.62%
  • Westfield Capital Management Company, LP

    4.39%

Corporate Announcements

  • Rocket Pharmaceuticals Inc Earnings

    Rocket Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Organization
Rocket Pharmaceuticals Inc
Employees
268
CEO
Dr. Gaurav D. Shah M.D.
Industry
Health Technology

FAQs